European journal of cardiovascular nursing · 2026
Efficacy and safety of operator-directed, nurse-administered propofol sedation in atrial fibrillation ablation.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park Jinsun, Cha Myung-Jin, Cho Min Soo, Nam Gi-Byoung, Choi Kee-Joon, Kim Jun
Аннотация
AIMS: Adequate sedation and analgesia are essential for catheter ablation of atrial fibrillation (AF) to ensure patient comfort and procedural safety. However, the availability of cardiac anaesthesiology is limited. This study evaluated the efficacy and safety of an operator-directed, nurse-administered (ODNA) sedation protocol using propofol and remifentanil during AF ablation.
METHODS AND RESULTS: In this prospective, single-centre observational cohort study, consecutive patients undergoing catheter ablation for AF from August 2023 to March 2024 were enrolled. Sedation-related adverse events and intra-procedural vital signs were recorded. Sedation depth was assessed using the Modified Observer's Alertness/Sedation (MOAA/S) scale, and patient satisfaction was evaluated using the Visual Analogue Scale (VAS). A total of 230 patients were included (mean age 61.9 years; 76.1% male). Of these, 7.4% had a body mass index of ≥30 kg/m2, and 4.3% had obstructive sleep apnoea. Paroxysmal AF accounted for 30.9%, and the mean procedure time was 174 min. The primary outcome-defined as unplanned sedation interruption, intubation, or continuous vasopressor requirement-occurred in 2.2% of patients. Intermittent hypotension (mean arterial pressure: <60 mmHg) occurred in 36.1% of patients, but no patient required continuous vasopressors. The mean MOAA/S score was 0.4 ± 0.4. Post-procedural surveys showed high satisfaction (mean VAS: 8.8) and low maximal pain (VAS: 0.9).
CONCLUSION: An ODNA protocol using propofol and remifentanil provides effective and safe sedation for AF ablation, with high patient satisfaction and minimal serious adverse events.
METHODS AND RESULTS: In this prospective, single-centre observational cohort study, consecutive patients undergoing catheter ablation for AF from August 2023 to March 2024 were enrolled. Sedation-related adverse events and intra-procedural vital signs were recorded. Sedation depth was assessed using the Modified Observer's Alertness/Sedation (MOAA/S) scale, and patient satisfaction was evaluated using the Visual Analogue Scale (VAS). A total of 230 patients were included (mean age 61.9 years; 76.1% male). Of these, 7.4% had a body mass index of ≥30 kg/m2, and 4.3% had obstructive sleep apnoea. Paroxysmal AF accounted for 30.9%, and the mean procedure time was 174 min. The primary outcome-defined as unplanned sedation interruption, intubation, or continuous vasopressor requirement-occurred in 2.2% of patients. Intermittent hypotension (mean arterial pressure: <60 mmHg) occurred in 36.1% of patients, but no patient required continuous vasopressors. The mean MOAA/S score was 0.4 ± 0.4. Post-procedural surveys showed high satisfaction (mean VAS: 8.8) and low maximal pain (VAS: 0.9).
CONCLUSION: An ODNA protocol using propofol and remifentanil provides effective and safe sedation for AF ablation, with high patient satisfaction and minimal serious adverse events.